Vanderbilt Vaccine Center
Antibody mixture may help block Ebola virus infection
Feb. 6, 2020—A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
VUMC-led team isolates antibody that blocks bird flu
Dec. 12, 2019—VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.
New tool may speed antibody, vaccine research
Dec. 12, 2019—Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues.
Partnership to help bring Zika virus therapy to clinic
Sep. 4, 2019—Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.
Vanderbilt vaccine pioneer James Crowe honored with major science prize
Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
New method tested to block chikungunya infection
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
VUMC joins international effort to speed vaccine development
Jun. 6, 2019—VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
Flu’s “hidden target” may lead to universal vaccine: study
May. 16, 2019—The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much.
Vanderbilt Vaccine Center Seminar Series: Brandon DeKosky May 6
Apr. 30, 2019—The Vanderbilt Vaccine Center Seminar Series presents Brandon DeKosky, assistant professor of chemical engineering and pharmaceutical chemistry at the University of Kansas, on Monday, May 6.
VUMC chikungunya antibody set to enter clinical trial
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Researchers push forward frontiers of vaccine science
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Designing antibodies to fight the flu
Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.